Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

華潤醫藥集團有限公司
China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

PRELIMINARY FINANCIAL INFORMATION OF CR SANJIU FOR THE SIX MONTHS ENDED 30 JUNE 2026

On 14 July 2026, CR Sanjiu released its unaudited preliminary financial information for the six months ended 30 June 2026.

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (華潤三九醫藥股份有限公司) ("**CR Sanjiu**") is a company incorporated in the People's Republic of China. The shares of CR Sanjiu are listed on the Shenzhen Stock Exchange. As of the date of this announcement, CR Sanjiu is indirectly owned as to 63.22% by China Resources Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") and is a subsidiary of the Company.

On 14 July 2026, CR Sanjiu released its unaudited preliminary financial information for the six months ended 30 June 2026 (the "**Reporting Period**") (the "**CR Sanjiu Preliminary Financial Information**"). Set out below are the key financial information of the CR Sanjiu Preliminary Financial Information:

I. MAJOR FINANCIAL INFORMATION AND INDICATORS FOR SIX MONTHS ENDED 30 JUNE 2026 (UNAUDITED)

Unit: RMB ten thousand

Item	The Reporting Period	The corresponding period of previous year	Increase/ decrease (%)
Total operating revenue	1,501,312.07	1,481,016.02	1.37%
Operating profit	249,841.08	262,093.86	–4.67%
Total profit	253,407.70	262,539.21	–3.48%
Net profit attributable to the shareholders of the listed company	167,187.58	181,525.84	–7.90%
Net profit attributable to the shareholders of the listed company (excluding extraordinary gains or losses)	159,807.37	169,770.91	–5.87%
Basic earnings per share *(RMB)*	1.00	1.09	–8.26%
Weighted average return on net asset *(%)*	7.32%	8.80%	Lower by 1.48%

Item	As of the end of the Reporting Period	As of the beginning of the Reporting Period	Increase/ decrease (%)
Total assets	5,585,748.57	5,880,467.87	–5.01%
Equity attributable to the shareholders of the listed company	2,287,422.61	2,217,174.12	3.17%
Share capital	166,421.79	166,421.79	0.00%
Net assets per share attributable to the shareholders of the listed company *(RMB)*	13.74	13.32	3.15%

Note:

(1) The above information is based on information from unaudited consolidated financial statements. The financial information set out in the 2026 interim report to be published by CR Sanjiu shall prevail.

II. DETAILS OF OPERATING RESULTS AND FINANCIAL POSITIONS

CR Sanjiu closely followed the national pharmaceutical industry development strategy, grounded in the pursuit of innovation-led advancement of traditional Chinese medicine and the upgrading of industrial quality, to support of building a healthy China. In the first half of 2026, facing a complex and evolving market environment, CR Sanjiu aligned its efforts around its strategic direction, anchored by its corporate mission of "caring for public health, co-creating a better life." It adhered to the two-wheel driven "innovation + brand," focused on core therapeutic areas, strengthened R&D innovation and digital-intelligence enablement, consolidated the "one core, two wings" business structure, deepened brand core competitiveness, optimised its business layout, forged comprehensive competitive advantages across the full industry chain, and reinforced its leading position in the industry. During the Reporting Period, CR Sanjiu achieved total operating revenue of RMB15.013 billion, representing a year-on-year increase of 1.37%, net profit attributable to shareholders of the listed company of RMB1.672 billion, representing a year-on-year decrease of 7.90%, and net profit attributable to shareholders of the listed company (excluding extraordinary gains or losses) of RMB1.598 billion, representing a year-on-year decrease of 5.87%.

The CR Sanjiu Preliminary Financial Information have been prepared in accordance with the PRC Generally Accepted Accounting Principles and are unaudited. The final audited results for the Reporting Period to be disclosed by CR Sanjiu in its 2026 interim report shall prevail.

The financial information is limited to CR Sanjiu only and does not represent or provide a complete view of the operational or financial status of the Group. **Shareholders and potential investors should exercise caution when dealing in securities of the Company and should not rely solely on such information.**

For further details of the CR Sanjiu audited interim financial results, please refer to the interim report for the six months ended 30 June 2026 to be published by CR Sanjiu on the website of the Shenzhen Stock Exchange (www.szse.cn).

By Order of the Board
China Resources Pharmaceutical Group Limited
Mr. Bai Xiaosong
Chairman

PRC, 14 July 2026

As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive director of the Company; Mr. Cheng Jie and Mr. Liu Changan as executive directors of the Company; Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mdm. Zhang Jing and Mdm. Jiao Ruifang as non-executive directors of the Company and Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian and Mr. Shi Luwen as independent non-executive directors of the Company.